Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $121000.0.

  • Pulmonx's Change in Account Payables fell 9102.37% to $121000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 6140.62%. This contributed to the annual value of $2.3 million for FY2024, which is 76028.99% up from last year.
  • Pulmonx's Change in Account Payables amounted to $121000.0 in Q3 2025, which was down 9102.37% from $2.1 million recorded in Q2 2025.
  • Pulmonx's 5-year Change in Account Payables high stood at $2.6 million for Q3 2021, and its period low was -$2.8 million during Q4 2021.
  • Moreover, its 5-year median value for Change in Account Payables was $121000.0 (2025), whereas its average is $264894.7.
  • Per our database at Business Quant, Pulmonx's Change in Account Payables plummeted by 211111.11% in 2022 and then skyrocketed by 4290000.0% in 2025.
  • Pulmonx's Change in Account Payables (Quarter) stood at -$2.8 million in 2021, then skyrocketed by 70.54% to -$830000.0 in 2022, then plummeted by 104.58% to -$1.7 million in 2023, then surged by 58.78% to -$700000.0 in 2024, then skyrocketed by 117.29% to $121000.0 in 2025.
  • Its Change in Account Payables was $121000.0 in Q3 2025, compared to $2.1 million in Q2 2025 and $505000.0 in Q1 2025.